Navidea Biopharmaceuticals Inc (NAVB)

[casperboo]

The market saw through Duncan's obviously distorted and fraudlent smear of the company, yet, the market is temporarily ignoring the milestone of Lymphoseek approval by the FDA. More unexpected that I was expecting, though not this particular scenario of a 2.67 close two days after approval. Like I have said before, I never expected the heavy shorting to accompany an early approval. I was outspoken in my belief that early approval was unlikely - I was incorrect. The FDA waited until the last day to issue the CRL and delayed the initial NDA by 90 days - all of which battered the share price. The biggest milestone in years for this company has now been treated like a nonevent...for now. What's next? Darned if I know, except that I am a buyer in the 2.67 and lower range if the sellers and shorts will be so kind.